Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin Post-AlloSCT in CD30+ Hodgkin Lymphoma
NCT02098512Phase 2
Key facts
- Status
- Unknown
- Start
- Mar 2014
- Primary completion
- Dec 2021
- Countries
- 1
- Sponsor
- New York Medical College
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Drugs
- brentuximab vedotin
- Conditions
- Hodgkin lymphoma (HL)
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL), sponsored by New York Medical College. Primary endpoints: Safety at 1 year and Overall Survival at 1 year. Status: unknown.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Allogeneic Transplant and Immunotherapy
RIC + AlloSCT followed by Brentuximab Vedotin
03
Who it enrols
Patients aged 45 or younger with CD30+ relapsed or refractory Hodgkin Lymphoma, having a matched donor, and adequate organ function.
04
Endpoints
Primary
Safety
Overall Survival
Secondary
Feasibility of developing a bank of LMP-specific CTLs
Beyond the preview
Go deeper on NCT02098512.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098512.